# US 2015/0104500 A1 · Methods and Compositions for Preventing a Condition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104500 A1
- Document ID: US20150104500A1
- Status: Published application
- Kind: A1
- Application number: 14/472,197
- Filed: 2014-08-28
- Published: 2015-04-16
- Earliest claimed: 2010-08-09
- Assignees: Cyvax, Inc.
- Applicants: Cyvax, Inc.
- Inventors: Richard Markham
- Web page: https://patentgrep.com/patent/US20150104500A1

## CPC

- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/6031: {Proteins}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a. a nucleic acid sequence encoding an antigen or a fragment thereof fused to macrophage inflammatory protein 3 alpha or a fragment thereof; and
b. an adjuvant.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antigen or a fragment thereof is a cancer antigen.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the antigen or a fragment thereof is from a parasite.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the adjuvant is a liposome.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a regulatory T-cell inhibitor.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the regulatory T-cell inhibitor is an siRNA.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the nucleic acid sequence is a plasmid.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the nucleic acid sequence encodes human macrophage inflammatory protein 3 alpha or a fragment thereof.

### Claim 15

A nucleic acid sequence encoding a parasite antigen fused to macrophage inflammatory protein 3 alpha.

### Claim 16 (depends on 15)

The nucleic acid sequence of claim 15 wherein the parasite is Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria, or Plasmodium yoelii.

### Claim 17 (depends on 16)

The nucleic acid sequence of claim 16 wherein the antigen is a circumsporozoite protein or fragment thereof.

### Claim 18 (depends on 17)

The nucleic acid sequence of claim 17 wherein the circumsporozoite protein or fragment thereof is from Plasmodium falciparum.

### Claim 19 (depends on 17)

The nucleic acid sequence of claim 17, wherein the nucleic acid sequence encodes human macrophage inflammatory protein 3 alpha or a fragment thereof.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

A method for eliciting an immune response in a subject comprising administering to the subject a pharmaceutical composition comprising a nucleic acid sequence encoding a parasite antigen or fragment thereof fused to an immune cell product.

### Claim 41 (depends on 40)

The method of claim 40 wherein the pharmaceutical composition further comprises an adjuvant.

### Claim 42 (depends on 41)

The method of claim 41 wherein the adjuvant comprises a commixture of GAPDMORIE and DPyPE.

### Claim 43 (depends on 40)

The method of claim 40 wherein the immune cell product is macrophage inflammatory protein 3 alpha.

### Claim 44 (depends on 40)

The method of claim 40 wherein the parasite antigen is from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria, or Plasmodium yoelii.

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48 (depends on 40)

The method of claim 40 wherein the pharmaceutical composition comprises the regulatory T-cell inhibitor.

### Claim at position 49

-98. (canceled)
